Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.
Authors
W. Clay Gustafson
Revolution Medicines, Redwood City, CA
W. Clay Gustafson , David Wildes , Meghan A. Rice , Bianca J. Lee , Jingjing Jiang , Zhengping Wang , Stephanie Chang , Mike Flagella , Yunming Mu , Nuntana Dinglasan , Nicole Nasholm , James W. Evans , Kyle Seamon , Jim Cregg , Alun Bermingham , Rebecca Freilich , Adrian L. Gill , Elena Koltun , Jacqueline A Smith , Mallika Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.591
Abstract #
591
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).
First Author: Ben George
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
First Author: Razia Aslam
Poster
2022 ASCO Annual Meeting
Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.
First Author: Bennett Adam Caughey
Poster
2021 ASCO Annual Meeting
Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
First Author: Justin Wayne Wong Tiu-lim